Blueprint Medicines Management
Management criteria checks 2/4
Blueprint Medicines' CEO is Kate Haviland, appointed in Apr 2022, has a tenure of 2.58 years. total yearly compensation is $6.43M, comprised of 12.2% salary and 87.8% bonuses, including company stock and options. directly owns 0.094% of the company’s shares, worth €5.37M. The average tenure of the management team and the board of directors is 4.2 years and 9.5 years respectively.
Key information
Kate Haviland
Chief executive officer
US$6.4m
Total compensation
CEO salary percentage | 12.2% |
CEO tenure | 2.6yrs |
CEO ownership | 0.09% |
Management average tenure | 4.2yrs |
Board average tenure | 9.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$128m |
Jun 30 2024 | n/a | n/a | -US$205m |
Mar 31 2024 | n/a | n/a | -US$288m |
Dec 31 2023 | US$6m | US$782k | -US$507m |
Sep 30 2023 | n/a | n/a | -US$555m |
Jun 30 2023 | n/a | n/a | -US$554m |
Mar 31 2023 | n/a | n/a | -US$581m |
Dec 31 2022 | US$6m | US$701k | -US$558m |
Sep 30 2022 | n/a | n/a | -US$718m |
Jun 30 2022 | n/a | n/a | -US$702m |
Mar 31 2022 | n/a | n/a | -US$650m |
Dec 31 2021 | US$4m | US$501k | -US$644m |
Sep 30 2021 | n/a | n/a | -US$411m |
Jun 30 2021 | n/a | n/a | US$340m |
Mar 31 2021 | n/a | n/a | US$325m |
Dec 31 2020 | US$2m | US$461k | US$314m |
Sep 30 2020 | n/a | n/a | US$333m |
Jun 30 2020 | n/a | n/a | -US$395m |
Mar 31 2020 | n/a | n/a | -US$371m |
Dec 31 2019 | US$3m | US$432k | -US$348m |
Sep 30 2019 | n/a | n/a | -US$362m |
Jun 30 2019 | n/a | n/a | -US$340m |
Mar 31 2019 | n/a | n/a | -US$267m |
Dec 31 2018 | US$3m | US$393k | -US$237m |
Sep 30 2018 | n/a | n/a | -US$205m |
Jun 30 2018 | n/a | n/a | -US$170m |
Mar 31 2018 | n/a | n/a | -US$177m |
Dec 31 2017 | US$1m | US$353k | -US$148m |
Compensation vs Market: Kate's total compensation ($USD6.43M) is above average for companies of similar size in the German market ($USD3.48M).
Compensation vs Earnings: Kate's compensation has increased whilst the company is unprofitable.
CEO
Kate Haviland (48 yo)
2.6yrs
Tenure
US$6,432,012
Compensation
Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2.6yrs | US$6.43m | 0.094% € 5.4m | |
Co-Founder & Director | no data | US$397.33k | 0.11% € 6.4m | |
Chief Financial Officer | 8.8yrs | US$2.19m | 0.056% € 3.2m | |
Chief Operating Officer | 2.6yrs | US$2.81m | 0.043% € 2.4m | |
Chief Scientific Officer | 3.5yrs | US$2.30m | 0.078% € 4.4m | |
President of Research & Development | 4.2yrs | US$2.80m | 0.050% € 2.9m | |
Senior VP | 1.8yrs | no data | 0.023% € 1.3m | |
Senior Director & Head of Investor Relations | no data | no data | no data | |
Executive VP | 8.2yrs | US$2.34m | 0.046% € 2.6m | |
Chief People Officer | 4.8yrs | no data | 0.019% € 1.1m | |
Senior Vice President of Corporate Affairs | no data | no data | no data | |
Chief Medical Officer | 4.5yrs | no data | 0.046% € 2.6m |
4.2yrs
Average Tenure
54yo
Average Age
Experienced Management: 2L9's management team is considered experienced (4.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2.6yrs | US$6.43m | 0.094% € 5.4m | |
Co-Founder & Director | 13.6yrs | US$397.33k | 0.11% € 6.4m | |
Chair of Scientific Advisory Board | 12.5yrs | US$333.38k | no data | |
Lead Independent Director | 8.6yrs | US$452.33k | 0.017% € 986.4k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board & Independent Director | 13.6yrs | US$417.33k | 0.088% € 5.0m | |
Independent Director | 8.8yrs | US$419.33k | 0% € 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 2.9yrs | US$422.33k | 0.014% € 770.7k | |
Chairman | 10.3yrs | US$526.08k | 0.24% € 13.9m |
9.5yrs
Average Tenure
62yo
Average Age
Experienced Board: 2L9's board of directors are considered experienced (9.5 years average tenure).